2 Information about isatuximab

Marketing authorisation indication


Isatuximab (Sarclisa, Sanofi) in combination with pomalidomide and dexamethasone has a marketing authorisation 'for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy'.

Dosage in the marketing authorisation



The proposed list price for isatuximab in the company submission is £506.94 for a 100‑mg vial or £2,534.70 for a 500‑mg vial. The company has a commercial arrangement. This makes isatuximab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)